The Czech government is reportedly dismissing National Drug Coordinator Pavel Bém and dismantling the country’s internationally respected evidence-based drug policy model in a move experts warn could shift policy toward a more punitive and ideological direction.

At ICPR 2024, we talked to psychologist and psychotherapist Marc B. Aixalà about how so-called “bad trips” can be reframed as difficult but potentially transformative experiences, and the importance of integration in psychedelic therapy.

On 7 May 2026, PAREA convened the first European Forum of National Psychedelic Societies in Brussels, bringing together representatives from organisations in 25 countries working on psychedelic research, policy, and access across Europe. Watch key presentations on the state of psychedelic access in Europe, filmed by Drugreporter.

How could evidence-based psychedelic therapies help address war-related mental health challenges in Ukraine, particularly PTSD among veterans? This was the main question of the European Parliament event held on 6 May, which Drugreporter captured on video in its entirety. Watch the full session now!

As civic space shrinks and organized crime grows, the Nordic countries are at a crossroads. This conference brought together activists, researchers, policymakers, and people who use drugs to discuss solutions rooted in Nordic values. Watch all presentations filmed by Drugreporter here!

The meeting of the UN Commission on Narcotic Drugs held in Vienna this spring showed how international drug policy is moving slowly. That is why every entry on harm reduction, human rights and public health is politically significant – a guest article by Aleksi Hupli, a Finnish researcher, first published in Finnish by A-Clinic Foundation.

Tadeusz Hawrot is the founder of the Psychedelic Access and Research European Alliance (PAREA), a Brussels-based initiative working to prepare Europe for the integration of psychedelic-assisted therapies into healthcare systems. In this interview, he reflects on the policy landscape, regulatory challenges, and the future of access to these emerging treatments in the EU.

With the new EU drug strategy now adopted, key questions remain about its direction and implementation—especially the balance between public health, human rights, and security. We spoke with Anna Dovbakh, Chair of the Civil Society Forum on Drugs, about what the strategy means in practice and the role of civil society moving forward.

As Hungary heads toward a pivotal election, the camera turns on two of its most prominent drug policy advocates. In this interview conducted by Arild Knutsen, Drugreporter founders Péter Sárosi and István Gábor Takács reflect on decades of activism—and explain why they are now taking their fight to the streets to challenge an increasingly repressive system.

The global drug control system is under growing pressure, as countries experiment with regulation and long-standing assumptions are being challenged. Martin Jelsma, who is stepping down from the Transnational Institute this year after decades of work, has been at the forefront of these debates. In this interview, we discuss the WHO’s coca review, inter se treaty reform, and what these shifts mean for the future of global drug policy.